Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...

D Molecular Therapeutics, Inc. ( (FDMT) ) has released its Q3 earnings. Here is a breakdown of the information 4D Molecular Therapeutics, Inc.

Wet AMD is caused by an overgrowth of blood vessels in the retina, the light-sensing tissue at the back of the eye. The ...

Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a ...

The company will use the proceeds to develop its gene therapies for eye disorders and for general corporate expenses.

The RD Fund launched Opus in the fall of 2021 ... retinitis pigmentosa, macular degeneration, and Usher syndrome. Visit FightingBlindness.org for more information.

A new study explains not only why some patients with wet age-related macular degeneration (or 'wet' AMD) fail to have vision improvement with treatment, but also how an experimental drug could be used ...

ONL Therapeutics Inc. is a classic case of a University of Michigan spinout. The Ann Arbor biotechnology startup netted the largest VC deal in the state in Q3, closing an oversubscribed $65 million ...